FATE - 2 Stocks to Hold for the Next 20 Years
As 2020 has demonstrated, the stock market can move in any direction in the short term. But as historical stock market data suggest, the stock market wields rock-solid wealth-building potential in the long run. That's why individual investors are best served by adopting a long-term mindset with a buy-and-hold strategy.
There are a number of ways to go about it. Most portfolios should own a collection of blue chip stocks, even if that simply relies on indexing, although buy-and-hold investing doesn't have to be boring. After all, investors that held onto today's blue-chip businesses before they were trendy have enjoyed awesome returns thanks to the power of compound interest.
With that in mind, investors might want to take a closer look at Dicerna Pharmaceuticals (NASDAQ: DRNA) and Fate Therapeutics (NASDAQ: FATE). The two development-stage biopharmas have much to prove, but these pharma stocks could appreciate considerably in the coming decades.